Molecular Mechanisms and Prognostic Factors in Colorectal Cancer

Colorectal cancer (CRC) arises through a constellation of genetic and epigenetic alterations that disrupt key cellular pathways governing proliferation, differentiation and genome integrity. Two principal models of genomic instability – chromosomal instability and microsatellite instability – underpin divergent routes of tumour initiation and progression. Core signalling cascades, including Wnt/β-catenin, MAPK, PI3K and TGFβ–SMAD, are frequently co-opted by somatic mutations in genes such as APC, KRAS, BRAF and TP53. Epigenetic aberrations, notably the CpG island methylator phenotype and deregulated microRNAs, further modulate gene expression programmes critical to tumour behaviour. Many tumours exploit epithelial–mesenchymal transition (EMT) and cancer stem cell hierarchies to acquire invasive and metastatic capacity, while remodelling of the tumour microenvironment – with recruitment of myeloid-derived suppressor cells and activation of immune checkpoint pathways – fosters immune evasion. Clinically relevant prognostic markers now extend beyond classic TNM staging to encompass molecular subtypes defined by transcriptomic classifiers, microsatellite status, mutational profiles and novel biomarkers such as TBL1XR1 and SOX9. Advances in spatial transcriptomics, circulating tumour DNA assays and machine-learning algorithms are driving precision prognostication and personalised therapeutic strategies worldwide.

Research from Nature Portfolio

Recent studies have illuminated the prognostic impact of transcriptional regulators in CRC. One investigation established that elevated expression of TBL1XR1 in primary tumours is an independent predictor of post-operative recurrence and poor disease-free survival, acting in part through modulation of β-catenin signalling and tumour cell oncogenicity. In a second line of work, SOX9 was shown to govern stem-like cell plasticity and metastatic competence in matched primary and metastatic CRC cell models. Pharmacological inhibition of mTOR with rapamycin attenuated SOX9-driven self-renewal, migration and tumour initiation in vivo, offering a compelling strategy to curb metastatic dissemination.

Molecular Mechanisms and Prognostic Factors in Colorectal Cancer publication trend

The graph below shows the total number of articles in molecular mechanisms and prognostic factors in colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Chromosomal instability (CIN): Frequent gains or losses of whole chromosomes leading to genetic heterogeneity in tumours.

Microsatellite instability (MSI): Accumulation of insertion/deletion mutations in short repetitive DNA sequences due to defective mismatch repair.

Cancer stem cell (CSC): A subpopulation of tumour cells with self-renewal capacity and driving metastasis and therapy resistance.

Epithelial–mesenchymal transition (EMT): A phenotypic switch enabling epithelial cells to acquire motility and invasive properties.

Myeloid-derived suppressor cell (MDSC): An immunosuppressive cell type within the tumour microenvironment that inhibits anti-tumour immunity.

mTOR inhibitor: A compound that targets the mechanistic target of rapamycin pathway to impede cancer cell growth and stemness.

References

1. Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications. Journal of Nanobiotechnology (2024).
2. CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway. Cell Death & Disease (2023).
3. Correlations between TBL1XR1 and recurrence of colorectal cancer. Scientific Reports (2017).
4. SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin. Scientific Reports (2016).
5. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut (2022).
6. A principled machine learning framework improves accuracy of stage II colorectal cancer prognosis. npj Digital Medicine (2018).